Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC ... models of breast cancer and melanoma, this approach demonstrated multiple ...

In preclinical models of breast cancer and melanoma, this approach demonstrated multiple benefits ... Reference: Schrank BR, Wang Y, Wu A, et al. An antibody–toxin conjugate targeting CD47 linked to ...

In preclinical models of breast cancer and melanoma, this approach demonstrated ... More information: An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin ...

(PDCs) demonstrate tumor-selective delivery and potent anticancer activityPreclinical data show robust efficacy as ...

HOUSTON ― Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC ... models of breast cancer and melanoma, this approach ...

in early-stage choroidal melanoma. Bel-sar is from a novel class of virus-like drug conjugate therapies that Boston, Massachusetts-based Aura is developing for various oncology indications.

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC ... In preclinical models of breast cancer and melanoma, this approach ...

BNT111 is based on BioNTech’s fully owned, off-the-shelf FixVac platform, and encodes four melanoma-associated antigens. BioNTech plans to present data from the ongoing Phase 2 clinical trial ...

In preclinical models of breast cancer and melanoma, this approach demonstrated multiple benefits ... More information: An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin ...